←
Mischel Lab85 posts
Mischel Lab avatar

Mischel Lab

@mischellab

The Mischel lab studies extrachromosomal oncogene amplification and altered metabolism in cancer. Account managed by lab members. Retweets are not endorsement.

◷ Joined November 2019
Mischel Lab avatar
Mischel Lab@mischellab·4 Mar 2021

The Paul Mischel Laboratory has relocated to ChEM-H at Stanford @Stanford_ChEMH. Paul is Professor and Vice Chair of Research for the Department of Pathology, Stanford University School of Medicine @StanfordMed and Institute Scholar, ChEM-H, Stanford University.

Mischel Lab avatar
Mischel Lab@mischellab·16 Jun 2022

We are honored, grateful for the opportunity, and committed to working together to make a difference for patients with ecDNA-driven cancers. It is a thrill to work with such an amazing group of colleagues.

Mischel Lab avatar
Mischel Lab@mischellab·16 Jun 2022

The team, composed of investigators from 11 institutions across the US, UK, and Germany, will leverage our interdisciplinary expertise to tackle the questions of origin, function, and evolution of ecDNA in cancer.

Mischel Lab avatar
Mischel Lab@mischellab·16 Jun 2022

We are excited to share that the eDyNAmiC team has been chosen as a @CancerGrand, @theNCI & @CR_UK winner! #CancerGrandChallenges

Extrachromosomal DNA (ecDNA) are small rings of DNA that help tumours evolve and evade treatment. The eDyNAmiC team will look at ways to interfere with ecDNA, slow down tumour development & ultimately bring hope to patients whose cancers have become resistant to treatment. 4/6

Post attachment
Mischel Lab avatar
Mischel Lab@mischellab·24 Nov 2021

Congratulations to @kinglhung, @KatieEYost, @HowardYChang and colleagues on this landmark discovery published today in @Nature. We are thrilled to have worked together with you on this.

Our paper is out in @Nature! Extrachromosomal DNA molecules huddle together in cancer cells to activate oncogene expression (which we call ecDNA hubs). A great collaboration with @KatieEYost, @HowardYChang, @549nm, Zhe Liu, and others. (1/10) nature.com/articles/s41586-0…

Sihan Wu 吴思涵 avatar
⟳ Mischel Lab retweeted
Sihan Wu 吴思涵@SihanSean·2 Nov 2021

Congrats to my former colleague Junfeng Bi @mischellab for the new paper! He found that GBM, the most lethal brain tumor, is sensitive to SMPD1 inhibition. Adding antidepressant fluoxetine to standard-of-care chemotherapy can improve patient survival. cell.com/cell-reports/fullte…

Mischel Lab avatar
Mischel Lab@mischellab·2 Nov 2021

The team found that GBMs are sensitive to SMPD1 inhibition and that fluoxetine can safely and potently shrink GBM tumors in mice. We also used real world data to identify that addition of fluoxetine to standard of care improves patient survival.

Mischel Lab avatar
Mischel Lab@mischellab·2 Nov 2021

Congratulations to postdoc Junfeng Bi on his new paper out today in @CellReports! It has important mechanistic and clinical implications for glioblastoma patients, spanning from fundamental biology, to clinical data. @Stanford_ChEMH @StanfordPath cell.com/cell-reports/fullte…

NatureRevClinOncol avatar
⟳ Mischel Lab retweeted
NatureRevClinOncol@NatRevClinOncol·15 Sep 2021

In uveal melanoma, PRC1 loss leads to gene de-repression, chromosome segregation errors, CIN, rupture-prone micronuclei & release of dsDNA into the cytosol, which activates the cGAS-STING pathway to induce inflammatory signalling & confers a poor prognosis nature.com/articles/s41467-0…

Ashley Laughney avatar
⟳ Mischel Lab retweeted
Ashley Laughney@LaughneyLab·15 Sep 2021

(1/2) Insights from #scRNAseq, coupled with fundamental #cell_biology, reveals loss of #PRC1 in a subset of tumor cells underlies transition of #uveal #melanoma from indolent to #metastatic phenotype. nature.com/articles/s41467-0… A team effort with @Samuel_Bakhoum @mischellab